ClinicalTrials.gg
CompletedNCT01324492\MACS1304Updated Dec 30, 2014

Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

A Phase 1 interventional study of RAD001 in Lung Neuroendocrine Neoplasm, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-12-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The present study is designed to collect safety/tolerability data and explore the efficacy of RAD001 in advanced pulmonary neuroendocrine tumor in Chinese patients.

02

Conditions studied

  • Lung Neuroendocrine Neoplasm

Keywords

  • phase Ib,
  • RAD001,
  • advanced pulmonary neuroendocrine tumor
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed carcinoid tumors
  • Newly diagnosed advanced carcinoid tumors or progressed after treatment is eligible

Exclusion criteria

Exclusion Criteria:

  • Patients with either clinically apparent central nervous system or carcinomatous meningitis(non-clinical symptoms with brain lesions is eligible)
  • Received Cytotoxic chemotherapy, immunotherapy or radiotherapy prior to enrollment
  • Patients with a concurrent , or history of prior malignancy within the past three years, except for basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, treated early stage (T1a) prostate cancer or treated early stage (DCIS or LCIS) breast cancer
  • Prior therapy with RAD001 or other mTOR inhibitors (sirolimus, temsirolimus, everolimus)

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    RAD001

    Drug: RAD001

Interventions

  • DrugRAD001

    Also known as: Everolimus

06

What researchers measure

Primary outcomes

  1. Adverse events, serious adverse events, laboratory results (Hematology, Serum Blood Chemistry, hepatitis tests, Standard urinalysis dipstick assessment, Coagulation Studies)or assessment of the incidence of pneumonitis

    Time frame: every 6 weeks

Secondary outcomes

  1. Chest X-Ray,Triphasic CT scan or MRI of the chest, abdomen and cavitas pelvis evaluated by using RECIST criteria

    Time frame: 6 weeks

  2. Date and reason of death, or discontinuation from the study.

    Time frame: 12 weeks

07

Study locations

4 sites
  • Novartis Investigative Site
    Beijing, Beijing 100730, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510030, China
  • Novartis Investigative Site
    Changchun, Jilin, China
  • Novartis Investigative Site
    Shenyang, Liaoning, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2011
First posted
Mar 29, 2011
Start
Dec 2010
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Last update
Dec 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01324492
Responsible party
Sponsor
First posted
Mar 29, 2011
Start date
Dec 2010
Primary completion
Jun 2014
Completion
Jun 2014
Last update
Dec 30, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
Novartis Pharmaceuticals
study director · Novartis Investigative Site
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion